NuVasive (NUVA) Appoints Daniel J. Wolterman as Independent Board Chair

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the appointment of Daniel J. Wolterman as independent chair of the NuVasive Board of Directors, effective immediately. Mr. Wolterman succeeds Gregory T. Lucier as the Company's Board chair, following Mr. Lucier's retirement from the Board on May 18, 2021.

"As a long-standing member of our Board of Directors, Dan's expertise and leadership will help NuVasive further execute on its long-term strategy," said J. Christopher Barry, chief executive officer of NuVasive. "His extensive experience in leading large, complex healthcare organizations will be an immense asset as NuVasive continues to scale and change the lives of patients around the world."

Mr. Wolterman joined the Company's Board in July 2015 and served as the Board's lead independent director since May 2020. He has nearly 40 years of healthcare experience, and most notably was the president and chief executive officer of Memorial Hermann Health System for 14 years, the largest not-for-profit health system in Southeast Texas. Mr. Wolterman earned a bachelor's degree in business administration and a master of business administration degree in finance from the University of Cincinnati, as well as a master's degree in healthcare administration from Xavier University. Mr. Wolterman also currently serves on the board of directors for Vizient, Inc.

"It is an honor to be appointed NuVasive Board Chair, and I am confident in the Company's ability to transform spine surgery and advance patient care," said Mr. Wolterman. "I look forward to continue helping NuVasive deliver value for shareholders as it becomes the largest spine technology company in the world."

The NuVasive Board of Directors is now comprised of nine directors and includes a diverse group of current and former executives in the healthcare, medical device, and technology sectors. Given the appointment of an independent Board chair, the Company will no longer designate a lead independent director of its Board.

You May Also Be Interested In

• Methanex (MEOH) Appoints Roger Perreault to its Board
• Volato (SOAR) Announces Board Changes
• SilverBow Resources (SBOW) Sends Letter to Shareholders Highlighting Path Forward for Value Creation